Ourobionics, a biotechnology company from the Netherlands, has introduced an innovative platform called CHIMERA. This new system integrates five biofabrication technologies, combining them for more efficient research and development.
Instead of juggling multiple machines, researchers can now use CHIMERA for various techniques like 3D Bio-ElectroSpraying, 3D Cell-ElectroSpinning, and more—all within one platform. This makes it easier to generate complex tissues using materials such as stem cells and organoids.
CHIMERA is designed to tackle key issues in cell-based manufacturing. Its modular setup allows scientists from different areas—like tissue engineering and synthetic biology—to collaborate more effectively.
With support from a significant 2024 investment round led by OostNL and the NXTGEN Hightech program, Ourobionics is set to enhance research in biomanufacturing and regenerative medicine.
“This platform changes the game for scientists and medical professionals,” says Dr. Ali Shooshtari, CTO of Ourobionics.
Key Features of CHIMERA
One standout feature of CHIMERA is its high cell viability, boasting up to 98% success for more than 56 types of cells, including stem cells and embryos. It’s fast too—able to produce 1cm³ structures in just about one minute, which is up to 30 times quicker than traditional methods.
The platform achieves fine detail with a resolution of up to 50nm, allowing for precise tissue scaffolding. It also uses encapsulation technology to handle various materials, supporting advancements in cell therapies and genetic engineering.
CHIMERA is versatile enough to work with different biomaterials, enhancing the adaptability of research teams. It ensures cells remain healthy throughout the process, tackling issues often encountered with conventional bioprinting.
This platform’s technologies take inspiration from research by Prof. Suwan Jayasinghe at University College London. Further improvements came from experts like Dr. Stephen G. Gray and Dr. Shooshtari, building on foundations laid at Imperial College London.
With over 150 studies validating its effectiveness, CHIMERA is poised to make an impact in both medical research and practical applications.
Progress in Biofabrication
Research in biofabrication is advancing rapidly. In February 2024, Carnegie Mellon University introduced a 3D ice printing method to create blood vessel-like structures. This technique uses specialized ice templates embedded in gelatin, which leaves hollow channels once the ice melts. It showed promise for long-term endothelial cell growth, supporting potential new therapies.
Prior to this, scientists from the University of Sydney and the Children’s Medical Research Institute developed a photolithographic printing technique to craft human tissues that mimic real organ structures. This method harnesses stem cells to form organized tissue, opening doors for applications in regenerative medicine and disease modeling.
As advancements in biofabrication continue, they hold the potential to revolutionize medical treatments and lead to greater understanding in tissue engineering.
Featured image shows the Ourobionics CHIMERA platform. Photo via Ourobionics.
Source link
Burak Ozdoganlar,Carnegie Mellon University,Children's Medical Research Institute,Dr. Peter Newman,Feimo Yang,imperial college london,Philip LeDuc,Professor Patrick Tam,University College London,University of Sydney
